Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying, Tabernanthalog Neuroplasticity Pathway, UK Eases Schedule I Research Restrictions

Pα+ Psychedelic Bulletin #206 compiles multiple updates on psychedelic policy, research, and industry activity. The bulletin reviews Q2 2025 federal lobbying disclosures, reporting that drug developers’ federal lobbying spend remained broadly stable, including notes on specific companies’ spending levels, lobbying firm changes, and the topics they are pushing with US institutions. It also covers research and neuroscience work around Tabernanthalog, highlighting findings that suggest neuroplasticity is influenced via an alternative pathway. Finally, the bulletin reports on UK regulatory movement toward easing Schedule I research restrictions, while keeping the industry at arm’s length, and it includes additional headlines such as lobbying backlash and an MDMA clinical practice guideline consultation.